CA 02604617 2013-08-15
= =
DESCRIPTION
COMPOSITION CONTAINING ANTI-DEMENTIA DRUG
Technical Field
The present invention relates to a composition containing anti-dementia drug.
More particularly, the present invention relates to a composition containing
at least
two kinds of anti-dementia drugs.
Background Art
In recent years, care for dementia such as senile dementia and Alzheimer-
type dementia has become a social problem, and Many therapeutic drugs for
dementia are being developed. Of these, donepezil, which has been supplied as
TM
the hydrochloride in a tablet or granule form (trade name Aricept,
manufactured by
Eisai Co., Ltd.), is seen as being highly useful as a therapeutic drug for
mild to
moderate Alzheimer-type dementia due to having an acetylcholinesterase
inhibiting
action. Moreover, memantine hydrochloride, which exhibits antagonism towards N-
methyl-D-aspartate (NMDA) receptors, has also been developed as a therapeutic
drug for moderate to severe Alzheimer-type dementia, and has been supplied in
a
film-coated tablet or liquid form (trade name Axura, manufactured by Merz
TM
Pharmaceuticals; trade name Namenda, manufactured by Forest Pharmaceuticals,
Inc.).
Recently, trials have been made using these two drugs together. It has
been reported that upon further administering memantine hydrochloride or a
placebo using a double blind test method to patients with moderate to severe
Alzheimer-type dementia who had already been administered donepezil
hydrochloride, for the group administered both donepezil hydrochloride and
1
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
memantine hydrochloride, cognitive ability and activities of daily living were
improved as compared to the group administered the placebo (see Non-Patent
Document 1). Moreover, the idea of a preparation containing an
acetylcholinesterase inhibitor and an NMDA receptor antagonist has also been
disclosed (see Patent Document 1, and Patent Document 2).
Meanwhile, most Alzheimer-type dementia patients not only have reduced
cognitive ability, but also have difficulty in swallowing, and so sufficient
care must
be taken with regard to compliance by the patients themselves, and also
reducing
the burden on care-givers. However, in the case of a therapeutic method in
which
commercially available products are used together, it is necessary, for
example, to
administer one donepezil hydrochloride tablet once per day, and further
administer
one memantine hydrochloride tablet twice per day; the frequency of
administration
and the amounts taken are thus high, and hence problems have arisen with
regard
to compliance. Moreover, in the case of a composition containing two or more
kinds of drugs, the drugs have different solubilities and pKa values to one
another.
It is thus difficult to simultaneously control the release of two or more anti-
dementia
drugs in a single dosage form, and the current state of affairs is that
specific control
methods for anti-dementia drugs have not been disclosed in any publicly known
literature, and furthermore there have also been no suggestions with regard to
the
need to improve compliance, or techniques for producing a preparation giving a
combined effect of two or more anti-dementia drugs used together.
Patent Document 1 : International Publication No. 03/101458
Patent Document 2: U.S. Patent Application Publication No. 2004/0087658
2
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
Non-Patent Document 1 : Pierre N. Tariot et al., "Memantine Treatment in
Patients with Moderate to Severe Alzheimer Disease Already Receiving
Donepezil ¨ a Randomized Controlled Trial", JAMA, Vol. 291, No. 3, p. 317-324
Disclosure of Invention
Problems to be Solved by the Invention
As described above, for the case of implementing therapy in which at least
two kinds of anti-dementia drugs are used together, there is a demand for a
composition which has a good therapeutic effect on dementia, and which also
gives
excellent compliance. More specifically, there is a demand for a composition
containing at least two kinds of anti-dementia drugs, for which release of the
anti-
dementia drugs from the composition is controlled, whereby a combined effect
of
the anti-dementia drugs can be achieved well. Furthermore, there is a demand
for
the development of a composition containing at least two kinds of anti-
dementia
drugs, according to which the frequency of administration and the amount taken
are
reduced, and hence compliance can be improved.
Moreover, from the standpoint of productivity and cost, there is a demand for
the development of a composition which can be easily manufactured and which
enables the release of at least two kinds of drugs to be easily controlled in
accordance with the object.
Furthermore, there is a demand for a composition in which the blood
concentration profiles for donepezil hydrochloride and memantine hydrochloride
are
equivalent to one another, or a pharmaceutical preparation in which, for each
drug,
there is an equivalent relationship between dissolution in an acidic solution
and
dissolution in a neutral solution so that the blood concentration profile for
the drug
is not affected by the gastric emptying time.
3
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
Means for Solving the Problems
In view of the above circumstances, the present inventors carried out
assiduous studies in the quest for a composition which contains at least two
kinds
of anti-dementia drugs, and which is effective for dementia, and furthermore
can be
administered as infrequently as once per day, and hence gives excellent
compliance. As a result, the present inventors have discovered that the
desired
objects can be attained through the following construction, thus arriving at
the
present invention.
In other words, the present invention provides a composition containing at
least two kinds of anti-dementia drugs. In a preferable aspect of the present
invention, the above composition contains at least one sustained-release
portion
containing at least one of the anti-dementia drugs. In another preferable
aspect of
the present invention, the above composition contains at least one quick-
release
portion containing at least one of the anti-dementia drugs. In a more
preferable
aspect of the present invention, the above composition contains at least one
sustained-release portion containing at least one of the anti-dementia drugs,
and at
least one quick-release portion containing at least one of the anti-dementia
drugs.
The present invention provides a composition containing at least two kinds
of anti-dementia drugs, wherein the anti-dementia drugs comprise a combination
of
a cholinesterase inhibitor and a compound having a mechanism of action
different
from that of the cholinesterase inhibitor. In a preferable aspect of the
present
invention, there is provided the composition in which the anti-dementia drugs
comprise at least one cholinesterase inhibitor and at least one N-methyl-D-
aspartate receptor antagonist. In a more preferable aspect of the present
invention,
there is provided the composition in which the anti-dementia drugs comprise
4
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
donepezil or a pharmacologically acceptable salt thereof, and memantine or a
pharmacologically acceptable salt thereof.
In a preferable aspect of the present invention, there is provided the above
composition wherein the anti-dementia drug contained in the sustained-release
portion is memantine hydrochloride. In a more preferable aspect of the present
invention, there is provided the above composition wherein the anti-dementia
drug
contained in the sustained-release portion is memantine hydrochloride, and the
anti-dementia drug contained in the quick-release portion is donepezil
hydrochloride. In another preferable aspect of the present invention, there is
provided the above composition containing two kinds of the sustained-release
portions, wherein the anti-dementia drug contained in one sustained-release
portion is memantine hydrochloride, and the anti-dementia drug contained in
the
other sustained-release portion is donepezil hydrochloride.
In a preferable aspect of the present invention, there is provided the above
composition wherein the anti-dementia drug contained in the sustained-release
portion is donepezil hydrochloride. In a more preferable aspect of the present
invention, there is provided the above composition wherein the anti-dementia
drug
contained in the sustained-release portion is donepezil hydrochloride, and the
anti-
dementia drug contained in the quick-release portion is memantine
hydrochloride.
The present invention provides a composition in which the sustained-release
portion contains at least one selected from non-pH-dependent polymeric
substances and pH-dependent polymeric substances. In a preferable aspect of
the
present invention, the non-pH-dependent polymeric substance comprises a water-
insoluble polymeric substance. In another preferable aspect of the present
invention, the pH-dependent polymeric substance comprises an enteric polymeric
substance. In a more preferable aspect of the present invention, the non-pH-
5
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dependent polymeric substance comprises a water-insoluble polymeric substance,
and the pH-dependent polymeric substance comprises an enteric polymeric
substance. In yet another preferable aspect of the present invention, there is
provided the above composition wherein the sustained-release portion comprises
granules or a compression-molded product.
In a preferable embodiment of the present invention, there is provided a
composition in which dissolution of anti-dementia drugs can be controlled in
accordance with the object. For example, according to the present invention,
there
is provided a composition in which dissolution of donepezil hydrochloride and
memantine hydrochloride can be controlled. Specifically, the composition of
the
present invention can be specified by the dissolution profile or the change in
dissolution percentage with dissolution time in an in vitro dissolution test,
or the f2
function value or the like. In this case, for such a composition, at least two
kinds of
drugs can be released from a carrier having the same composition.
According to the present invention, there can be provided, as a composition
in which two kinds of anti-dementia drugs are made to be sustained-release, a
composition specified by specific dissolution profiles in a neutral
dissolution test
solution. It can be made to be such that at least 80% of each of at least two
kinds
of anti-dementia drugs is released in a specified dissolution time of 3 to 10
hours.
In this case, the dissolution times for the anti-dementia drugs may be made to
be
the same as one another, or different to one another.
Further, according to the present invention, there can be provided a
composition in which one anti-dementia drug is released at an early stage in
an
acidic region, and another anti-dementia drug is released at a late stage in a
neutral region. For example, there can be provided a composition in which at
least
80% of one anti-dementia drug is released within a dissolution time of 3
hours, and
6
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
at least 80% of another anti-dementia drug is released in a specified
dissolution
time of 3 to 10 hours.
Furthermore, according to the present invention, there can be provided a
composition in which each of at least two kinds of anti-dementia drugs is
released
at an early stage in an acidic region. For example, there can be provided a
composition in which the dissolution percentage for each of the at least two
kinds of
anti-dementia drugs in an acidic dissolution test solution is at least 60% at
a
dissolution time of 1 hour.
Moreover, according to the present invention, there can be provided a
composition in which the dissolution profiles for at least two kinds of anti-
dementia
drugs are similar to or the same as one another. For example, the composition
can
be specified by a ratio of the dissolution percentages for the two kinds of
anti-
dementia drugs at certain dissolution times at which the dissolution
percentages
are compared, or the f2 function value.
Furthermore, according to the present invention, there can be provided a
composition in which the dissolution profile in an acidic dissolution test
solution and
the dissolution profile in a neutral dissolution test solution are closely
similar or
equivalent to one another for each of at least two kinds of anti-dementia
drugs. In
this case, the similarity or equivalency of the dissolution profiles can be
specified by
a ratio of the dissolution percentage in the acidic dissolution test solution
to the
dissolution percentage in the neutral dissolution test solution, or the f2
function
value.
Advantageous Effect of the Invention
According to the composition of the present invention, not only can the
effects of each of at least two kinds of anti-dementia drugs be achieved, but
7
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
moreover there can be provided a novel therapeutic method due to a synergistic
effect between these anti-dementia drugs. In particular, according to the
present
invention, there can be provided a composition containing anti-dementia drugs
in
which dissolution can be controlled in accordance with the symptoms and state
of
the patient and the therapeutic method. Furthermore, according to the
composition
of the present invention, there can be provided a medicine that gives
excellent
compliance and is of excellent quality, and can be taken without anxiety by a
patient exhibiting symptoms of dementia, or reduction in the burden on a care-
giver
administering the medicine can be realized. Furthermore, according to the
present
invention, design of a pharmaceutical preparation conforming to intended
objectives with regard to controlling release of the anti-dementia drugs can
be
carried out easily without using a special manufacturing apparatus, and
moreover
there can be provided a simple, convenient manufacturing method for a
pharmaceutical composition in which the anti-dementia drugs are stabilized.
Brief Description of Drawings
FIG. 1 is a table showing component mixing proportions for components in
examples of compositions according to the present invention;
FIG. 2 illustrates tables showing dissolution test evaluation results for
Examples 1 and 2;
FIG. 3 illustrates a table showing dissolution test evaluation results for
Examples 5 to 8;
FIG. 4 illustrates a table showing f2 function values for dissolution profiles
for
two kinds of anti-dementia drugs; and
FIG. 5 illustrates a table showing f2 function values for dissolution profiles
in
acidic and neutral dissolution test solutions.
8
CA 02604617 2012-09-25
=
Best Mode for Carrying Out the Invention
The following is a description of embodiments of the present invention.
However, the following embodiments are merely illustrative for explaining the
present invention, and it is not intended that the present invention be
limited only to
these embodiments. The invention can be implemented in various modes,
without departing from the invention, the scope of which is defined in the
appended claims.
(Anti-dementia drugs)
There are no particular limitations on an anti-dementia drug used in the
present invention, so long as this drug can be used as a drug for combating
dementia. The composition according to the present invention contains at least
two
kinds of such anti-dementia drugs. Examples of anti-dementia drugs that can be
used in the present invention include, but are not limited to, cholinesterase
inhibitors, NMDA receptor antagonists (e.g. memantine or the like), choline
uptake
enhancers (e.g. MKC-231 or the like), somatostatin release enhancers (e.g.
FK960
or the like), neurotransmitter regulators (e.g. nefiracetam or the like),
muscarinic M1
receptor agonists (e.g. talsaclidine or the like), benzodiazepine receptor
partial
inverse agonists (e.g. S-8510 or the like), and acetylcholine / noradrenaline
release
enhancers (e.g. T-588, T-817MA or the like) or the like. Examples of
cholinesterase inhibitors include, but are limited to, tacrine, rivastigmine,
galantamine, donepezil, physostigmine, pyridostigmine, neostigmine,
citicoline,
velnacrine, huperzine (e.g. huperzine A), metrifonate, heptastigmine,
edrophonium,
phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine,
341 -(phenylmethyl)piperidin-4-y11-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-0-1-
propane fumarate (hereinafter referred to as "TAK-147"), 5,7-dihydro-3-[241-
9
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
(phenylmethyl)-4-piperidinyl]ethy1]-6H-pyrrolo[4,54]-1,2-benzisoxazol-6-one
maleate (hereinafter referred to as "CP118954"), T-82, upreazine, and
pharmacologically acceptable salts thereof. Other examples of anti-dementia
drugs
include, but are not limited to, vitamin E, ginkgo leaf extract,
ubidecarenone, and
phosphatidyserine. Note that each anti-dementia drug may be used either in
free
form, or as an organic acid salt or inorganic acid salt, with an organic acid
salt or
inorganic acid salt being preferable, and an inorganic acid salt being
particularly
preferable.
Anti-dementia drugs preferably used in the present invention are tacrine,
rivastigmine, galantamine, donepezil, memantine, and pharmacologically
acceptable salts thereof, and also TAK-147, and CP118954. Particularly
preferable
anti-dementia drugs are tacrine, rivastigmine hydrogen tartrate, galantamine
hydrobromide, donepezil hydrochloride (chemical name ( )-2-[(1-benzylpiperidin-
4-
yl)methyl]-5,6-dimethoxyindan-1-one monohydrochloride), TAK-147, CP118954,
and memantine hydrochloride.
There are no particular limitations on the combination of anti-dementia drugs,
which may be a combination of anti-dementia drugs having the same mechanism of
action as one another, or a combination of anti-dementia drugs having
different
mechanisms of action to one another. An example is a combination of a
cholinesterase inhibitor, and a compound having a mechanism of action
different
from that of the cholinesterase inhibitor, with a combination of a
cholinesterase
inhibitor and an NMDA receptor antagonist being preferable, and a combination
of
donepezil or a pharmacologically acceptable salt thereof, and memantine or a
pharmacologically acceptable salt thereof being more preferable. A combination
of
donepezil hydrochloride and memantine hydrochloride is particularly
preferable.
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
Note that the composition according to the present invention may also contain
therapeutic drugs other than anti-dementia drugs.
(Doses of drugs)
There are no particular limitations on the dose of each of the anti-dementia
drugs for use in the composition of the present invention, but this dose is,
for
example, from 0.1 to 500 mg/day, preferably from 0.5 to 100 mg/day, more
preferably from 1 to 50 mg/day.
In the case of an acetylcholinesterase inhibitor, the dose is preferably from
0.5 to 50 mg/day, more preferably from 1 to 25 mg/day. Specific examples are
from 5 to 50 mg/day for tacrine or a pharmacologically acceptable salt
thereof, from
1 to 20 mg/day for donepezil or a pharmacologically acceptable salt thereof,
from 1
to 15 mg/day for rivastigmine or a pharmacologically acceptable salt thereof,
and
from 2 to 25 mg/day for galantamine or a pharmacologically acceptable salt
thereof.
Moreover, in the case of an NMDA receptor antagonist, the dose is from 0.1
to 500 mg/day, preferably from 0.5 to 100 mg/day, more preferably from 1 to 50
mg/day. A specific example is from 1 to 40 mg/day for memantine or a
pharmacologically acceptable salt thereof. The anti-dementia drug dose can be
divided with the composition being administered a plurality of times per day,
but the
composition is preferably administered not more than once per day. The
composition according to the present invention thus preferably contains at
least one
day's dose of each of the at least two kinds of the anti-dementia drugs.
(Control of release)
The composition according to the present invention enables controlled
release from the composition containing the at least two kinds of anti-
dementia
11
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
drugs to be attained easily; for example, a method and form of administration
in
which administration is carried out once per day or less frequently than this
can be
realized. The term "controlled release" used in the present invention means
that
the release of the drugs from the composition is controlled in accordance with
the
object. When realizing such controlled release in the present invention, the
release
of the at least two kinds of anti-dementia drugs can be controlled from a
single
preparation composition through either a sustained-release function or quick-
release function alone, or a combination thereof. The term "sustained-release"
herein not only indicates an anti-dementia drug being released more gradually
over
time than with quick-release, but also includes extended-release or pulsed-
release
in which release of the drug starts after a certain period of time, and
prolonged
release in which the drug concentration is maintained over time. Moreover,
with
"quick-release", the objective is for the drug to be released rapidly after
administration, for example for it to be possible to release at least 85% of
the anti-
dementia drug within 1 to 3 hours after commencement of dissolution in a
dissolution test.
With the composition according to the present invention, there are no
particular limitations on the combination of the kinds and amounts of the anti-
dementia drugs, or the types of controlled release. For example, in the case
that
there are two anti-dementia drugs, one anti-dementia drug may be made to be
quick-release, and the other sustained-release. That is, two anti-dementia
drugs
that have hitherto been administered with different frequencies, for example
an
anti-dementia drug hitherto administered twice per day and an anti-dementia
drug
hitherto administered once per day, can be combined into a composition of a
form
that is administered once per day. An example is a composition containing at
least
two kinds of anti-dementia drugs obtained by making an effective dose of an
anti-
12
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dementia drug that is usually administered twice per day such as tacrine,
memantine, galantamine or rivastigmine be sustained-release, and further
adding
donepezil, which is usually administered once per day.
As another example, one anti-dementia drug can be controlled to be quick-
release and sustained-release, while the other is made to be sustained-release
or
quick-release. An example is a composition in which10 mg of memantine
hydrochloride and 10 mg of donepezil hydrochloride are made to be quick-
release,
and another 10 mg of memantine hydrochloride is controlled so as to be
released 6
to 8 hours after administration.
As yet another example, two anti-dementia drugs that are usually used in
different dose regimens can both be made to be sustained-release, or both be
made to be quick-release. In this case, the methods of making the anti-
dementia
drugs be sustained-release or quick-release may be of the same type of control
of
release, or different types. For example, for a single composition, control
can be
carried out such that both 10 mg of donepezil hydrochloride and 20 mg of
memantine hydrochloride are released gradually 6 to 12 hours after
administration.
Alternatively, the control of release of the two drugs can be carried out such
that
the donepezil hydrochloride is released gradually 6 to 12 hours after
administration,
and the memantine hydrochloride is subjected to pulsed-release immediately
after
administration and 6 to 8 hours after administration.
Yet another example is a composition in which two anti-dementia drugs are
both controlled to be quick-release. An example is a composition containing 10
mg
of memantine hydrochloride and 10 mg of donepezil hydrochloride, this being a
composition enabling good anti-dementia effects to be achieved upon
administration only once per day and with a reduced dose of the drugs compared
to
the case of using together a commercially available preparation of 10 mg of
13
Our Ref: E0006 UP31W/1<AN CA 02604617 2007-10-12
memantine hydrochloride administered twice per day and a commercially
available
preparation of 10 mg of donepezil hydrochloride administered once per day. Yet
another example of a composition according to the present invention is a
composition comprising a quick-release portion, which may be a composition
containing 10 mg of memantine hydrochloride and 5 mg of donepezil
hydrochloride
that is administered twice per day. Note that in the case of making the
composition
according to the present invention contain memantine hydrochloride and
donepezil
hydrochloride, there are no particular limitations on the amounts of the
memantine
hydrochloride and the donepezil hydrochloride.
There are no particular limitations on each of the anti-dementia drugs
contained in the composition according to the present invention, but from the
standpoint of controlling release, a basic drug or salt thereof that is less
soluble in
an alkaline aqueous solution than in an acidic aqueous solution, and for which
the
solubility with pH of an aqueous solution changes around a neutral pH is
effective.
Moreover, according to the composition of the present invention, control can
be
carried out simultaneously for an anti-dementia drug for which the change in
solubility with pH of an aqueous solution around a neutral pH is relatively
small, and
an anti-dementia drug for which this change is relatively large. Each anti-
dementia
drug used in the present invention is, for example, a basic drug or a salt
thereof for
which the pKa of a basic functional group of the anti-dementia drug is from 7
to 12,
preferably from 7.5 to 11, more preferably from 8 to 10.5, most preferably
from 8.5
to 10.5. For example, donepezil hydrochloride is a basic drug with pKa = 8.90,
and
memantine hydrochloride is a basic drug with pKa = 10.27.
(Embodiment of composition)
14
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
The composition according to the present invention contains at least one
sustained-release portion for performing a sustained-release function when
controlling the release of the at least two kinds of anti-dementia drugs. The
composition further contains at least one quick-release portion for performing
a
quick-release function. Here, the term "containing at least one quick-release
portion or sustained-release portion" means that there may be one quick-
release
portion or sustained-release portion, or a plurality of quick-release portions
or
sustained-release portions, in the composition. A composition containing a
sustained-release portion containing at least one anti-dementia drug is
preferable.
Also preferable is a composition containing a quick-release portion containing
at
least one anti-dementia drug. More preferable is a composition containing a
sustained-release portion containing at least one anti-dementia drug, and a
quick-
release portion containing at least one 'other anti-dementia drug. Here, each
sustained-release portion in the present invention has a sustained-release
function
for at least one of the anti-dementia drugs. In this case, the form of the
composition may be such that one sustained-release portion constitutes the
whole
composition, or may be such that the composition has at least one sustained-
release portion as a part of the composition. Examples of the former include
tablets or granules having a sustained-release film coating, and a matrix type
sustained-release preparation having a wax or a resin as a base material.
Moreover, examples of the latter include tablets formed from a mixture of
sustained-release granules constituting a sustained-release portion and quick-
release granules constituting a quick-release portion, a capsule preparation
obtained by filling a capsule with sustained-release granules and quick-
release
granules, and press-coated tablets in which an outer layer constituting a
quick-
release portion is formed on an inner core constituting a sustained-release
portion.
CA 02604617 2012-09-25
Moreover, the composition may be of a type in which a tablet containing
sustained-
release granules constituting a sustained-release portion is further coated
with a
sustained-release film so as to give the composition as a whole a sustained-
release
function. There is, however, no limitation to the above embodiments. Moreover,
there are no particular limitations on the state of containment of each anti-
dementia
drug in the composition or in a quick-release portion or a sustained-release
portion;
the anti-dementia drug may be dispersed uniformly in the composition, quick-
release portion or sustained-release portion, or may be contained in only one
part
of the composition, quick-release portion or sustained-release portion, or may
be
contained such that there is a concentration gradient.
Specific embodiments of the composition according to the present invention
are given below, but there is no limitation thereto. Here, examples are given
of
various types of composition that can be administered once per day and
contain, as
the anti-dementia drugs, donepezil hydrochloride, which is usually
administered
once per day, and memantine hydrochloride, which is usually administered twice
per day.
(Matrix type preparation)
A first example is a matrix type preparation. An aqueous solution of
hydroxypropyl cellulose is added to a mixture of donepezil hydrochloride
(manufactured by Eisai Co. Ltd.), memantine hydrochloride (manufactured by
Lachema s.r.o., Czech Republic), ethylcellulose (Ethocel 10FP, manufactured by
Dow Chemical Company, USA), Eudragit L100-55 (manufactured by Rohm GmbH
& Co. KG, Darmstadt, Germany), and lactose, and wet granulation is carried
out,
and then the granules thus obtained are heat dried using a tray dryer, and
then
sieved to obtain the desired granule size. After sieving, magnesium stearate
is
16
CA 02604617 2012-09-25
= =
added to the sustained-release granules obtained and mixing is carried out,
and
then a rotary tabletting machine is used to form a tablet, whereby a tablet
containing 10 mg of donepezil hydrochloride and 20 mg of memantine
hydrochloride can be obtained. Alternatively, it is also possible to prepare
sustained-release granules for each of memantine hydrochloride and donepezil
hydrochloride, then add sodium stearyl fumarate and carry out mixing, and then
use a rotary tabletting machine to obtain a tablet. In this case, for each of
the types
of sustained-release granules, the amount of a non-pH-dependent polymeric
substance or a pH-dependent polymeric substance according to the present
invention can be varied in accordance with the release profiles of the two
drugs. In
any case, both donepezil hydrochloride and memantine hydrochloride can be made
to be sustained-release, and hence such a tablet can be used as a tablet form
administrable once per day.
(Gel matrix type preparation)
A second example is a gel matrix type preparation. Donepezil hydrochloride
(manufactured by Eisai Co. Ltd.), memantine hydrochloride (manufactured by
Lachema s.r.o., Czech Republic), and polyethylene oxide (Polyox , manufactured
by
Dow Chemical Company, USA), carboxyvinyl polymer (manufactured by BF
Goodrich), and hydroxypropyl cellulose, each of these three polymers being
water-
swellable or forming a gel in water, are mixed together, and compression-
molding
is carried out using a rotary tabletting machine, whereby a compression-molded
product can be obtained as a sustained-release portion. A film-coated tablet
can
then be obtained by using Opadry Yellow (Japan Colorcon) to further coat with
a
water-soluble film coating (coating amount: 5 mg/tablet) containing
hydroxypropyl
methylcellulose as a main component thereof. According to the resulting
tablet,
17
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
both donepezil hydrochloride and memantine hydrochloride can be made to be
sustained-release, and hence the tablet can be used as a tablet form
administrable
once per day.
(Multi-layer tablet)
A third example is a tablet in which a plurality of layers are stacked on one
another. These layers may be a combination of sustained-release portions and
quick-release portions having different functions as appropriate based on the
release profiles of the anti-dementia drugs. An example is a two-layer tablet
in
which a first layer constituting a quick-release portion contains donepezil
hydrochloride, and a second layer constituting a sustained-release portion
contains
memantine hydrochloride. In this case, Eudragit RS (manufactured by Rohm
GmbH & Co. KG, Darmstadt, Germany) and Eudragit L100-55 (manufactured by
ROhm GmbH & Co. KG, Darmstadt, Germany) are contained in the second layer.
Moreover, a sustained release function may be conferred using polyethylene
oxide
and carboxyvinyl polymer (manufactured by BF Goodrich) as for the gel matrix
type
preparation. Through such a construction, release of memantine hydrochloride
from the second layer can be made to be sustained while making release of
donepezil hydrochloride from the first layer quick. Moreover, in such a two-
layer
tablet, the drugs in the two layers can be replaced with one another, i.e.
such that
memantine hydrochloride is released quickly from the first layer, and
donepezil
hydrochloride is released in a sustained way from the second layer.
Alternatively,
the composition may be of a form administrable once per day in which the first
layer
is made to be a sustained-release portion containing 10 mg of donepezil
hydrochloride and 10 mg of memantine hydrochloride, and the second layer is
made to be a sustained-release portion from which 10 mg of memantine
18
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
hydrochloride is released in a pulsed way. Another example is a composition
that
is a two-layer tablet, with both layers being made to be a quick-release
portion, and
donepezil hydrochloride and memantine hydrochloride being contained in the
respective layers. In this case, the two quick-release portions may have the
same
quick-release function as each other, or different quick-release functions,
the
control of release being carried out freely in accordance with the kinds of
the anti-
dementia drugs and so on.
(Press-coated tablet)
A fourth example is a press-coated tablet having an inner core layer, and an
outer layer covering the inner core layer. Examples are as follows: (1) A
press-
coated tablet containing donepezil hydrochloride in the outer layer, which is
a
quick-release portion, and memantine hydrochloride in the inner core layer,
which
is a sustained-release portion. In this case, the inner core layer may contain
ethylcellulose (Ethocel 10FP, manufactured by Dow Chemical Company, USA) and
Eudragit L100-55 (manufactured by Rahm GmbH & Co. KG, Darmstadt, Germany),
so that release of the donepezil hydrochloride from the outer layer can be
made to
be quick, and release of the memantine hydrochloride from the inner core layer
can
be made to be sustained. (2) A composition in which both donepezil
hydrochloride
and memantine hydrochloride are released quickly from an outer layer
containing
both of these drugs, and then after a certain period of time has elapsed,
memantine
hydrochloride is released in a pulsed way from an inner core layer. To make
the
release pulsed, the inner core layer can be surrounded by a coating layer for
pulsed-release, or a disintegrant can be contained in the inner core layer.
(3) A
composition having as an inner core layer a two-layer tablet comprising a
quick-
release portion from which memantine hydrochloride is released quickly and a
19
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
sustained-release portion from which memantine hydrochloride is released in a
sustained way, and an outer layer containing donepezil hydrochloride.
(Multi-granule preparation)
A fifth example is a composition containing a plurality of types of granules.
Each of the types of granules can be made to be quick-release, sustained-
release,
pulsed-release or the like, so as to freely establish the desired dissolution
profile.
For example, (1) quick-release granules containing memantine hydrochloride,
sustained-release granules containing donepezil hydrochloride, and pulsed-
release
granules containing memantine hydrochloride can be contained in the
composition,
whereby upon one administration, the interval between the times when the blood
plasma concentration of memantine hydrochloride reaches a maximum can be
made to be 8 hours or more, and the donepezil hydrochloride can be released
gradually after administration. Alternatively, (2) a preparation form
administrable
once per day can be produced by making sustained-release granules for which
release commences 2 hours, 4 hours, 6 hours, or 8 hours after administration
contain 5 mg of memantine hydrochloride, and combining these with granules
from
which 10 mg of donepezil hydrochloride is released in a sustained way. There
is
no limitation to the above release profiles. Moreover, there are also no
limitations
on the dosage form of the preparation, which may be a granular preparation
obtained by mixing the various types of granules together, or alternatively a
tablet
obtained by compression molding the various types of granules, or a capsule
preparation obtained by filling the various types of granules into an HPMC
capsule
or the like.
(Multi-layered granules)
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
A sixth example is granules in which layers containing anti-dementia drugs
are multi-layered on core particles of Nonpareil or the like. An example is
granules
in which a plurality of layers containing the anti-dementia drugs are multi-
layered on
Nonpareil 101 by alternately coating with a film coating liquid containing
memantine
hydrochloride and a film coating liquid containing donepezil hydrochloride. In
this
case, release of the anti-dementia drugs may be controlled by changing the
concentration of the anti-dementia drug in each layer. Alternatively,
sustained-
release granules may be formed in which thin layers containing ethylcellulose
and a
plasticizer are provided between the layers containing the drugs and an
outermost
layer. Alternatively, a sustained-release function can be conferred to each of
the
layers containing the drugs by mixing the anti-dementia drug with
ethylcellulose,
Eudragit RS or the like in advance. Note that such granules can also. be
obtained
by using granules containing at least one anti-dementia drug as the core
particles
instead of Nonpareil, and multi-layering layers containing the same anti-
dementia
drug or a different anti-dementia drug on these core particles. The resulting
granules may be used alone, or a plurality of types of such granules may be
combined; the granules may be used as the composition according to the present
invention either as a granular preparation as is, or as a capsule preparation
filled
into HPMC capsules.
(Film-coated tablet)
A seventh example is a film-coated tablet. Memantine hydrochloride,
donepezil hydrochloride, crystalline cellulose, lactose, and corn starch are
mixed
together, an aqueous solution of hydroxypropyl cellulose is added thereto, and
wet
granulation is carried out, and then the granules thus obtained are heat dried
using
a tray dryer, and then sieved to obtain the desired granule size. After
sieving,
21
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
magnesium stearate is added to the quick-release granules obtained and mixing
is
carried out, and then a rotary tabletting machine is used to form a tablet,
whereby a
compression-molded product that is a quick-release portion containing
donepezil
hydrochloride and memantine hydrochloride is obtained. A quick-release film-
coated tablet can then be obtained by using Opadry Yellow (Japan Colorcon) to
further coat with a water-soluble film coating having hydroxypropyl
methylcellulose
as a main component thereof. Alternatively, instead of a water-soluble film
coating,
coating may be carried out with a mixture of a water-insoluble polymer such as
ethylcellulose or Eudragit RS, and a water-soluble polymer or a plasticizer,
so as to
obtain a sustained-release film-coated tablet. Moreover, taking the
compression-
molded product constituting the quick-release portion as mini-tablets, a
plurality of
film-coated tablets having different thicknesses or compositions of the
sustained-
release film may be prepared, and then filled into HPMC capsules.
An eighth example is a composition in which a compression-molded product
is taken as a quick-release portion, and sustained-release granules are
dispersed
in this compression-molded product. An example is a tablet obtained by mixing
memantine hydrochloride and ethylcellulose together, and granulating to
prepare
sustained-release granules, and then mixing these sustained-release granules
with
donepezil hydrochloride, a diluent, a binder and so on, and compression-
molding
this mixture. The sustained-release granules may be granules having a single
dissolution profile, or granules having a plurality of dissolution profiles as
in the fifth
example, or multi-layered granules as in the seventh example. Moreover, as the
sustained-release portion, instead of sustained-release granules, a liposome
or
micro-capsules containing an anti-dementia drug may be contained.
(Dosage form)
22
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
There are no particular limitations on the dosage form of the composition
according to the present invention, which may be any dosage form including
tablets,
capsules, granules, fine granules, a powder, orally rapid disintegrating
tablets, an
ointment, an injection, a poultice, a liquid, a preparation for per-tube
administration,
an inhalant, a jelly or the like. The dosage form is preferably one suitable
for oral
administration such as tablets, capsules, granules, fine granules, orally
rapid
disintegrating tablets, a liquid, a preparation for per-tube administration,
or a jelly,
with tablets, capsules, granules, fine granules, or orally rapid
disintegrating tablets
being particularly preferable.
(Additives for controlling release)
A sustained-release portion in the composition according to the present
invention contains at least one non-pH-dependent polymeric substance or pH-
dependent polymeric substance for controlling anti-dementia drug release, and
preferably contains such a non-pH-dependent polymeric substance and such a pH-
dependent polymeric substance.
(Non-pH-dependent polymeric substances)
The non-pH-dependent polymeric substance used in the present invention is
a polymeric substance whose charge state hardly changes under pH conditions
generally found in the gastrointestinal tract, specifically from pH 1 to pH 8.
This
means, for example, a polymeric substance that does not have functional groups
whose charge state changes depending on the pH such as basic functional groups
such as amino groups or acidic functional groups such as carboxylic acid
groups.
Note that in the present invention, the non-pH-dependent polymeric substance
can
be included for giving the composition according to the present invention a
23
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
sustained-release function, but may also be included for another purpose.
Moreover, the non-pH-dependent polymeric substance used in the present
invention may be water-insoluble, or may swell in water or dissolve in water
to form
a gel. Examples of water-insoluble non-pH-dependent polymeric substances
include, but are not limited to, cellulose ethers, cellulose esters, and
methacrylic
acid-acrylic acid copolymers (trade name Eudragit, manufactured by ROhm GmbH
& Co. KG, Darmstadt, Germany). Examples include, but are not limited to,
cellulose alkyl ethers such as ethylcellulose (trade name Ethocel,
manufactured by
Dow Chemical Company, USA), ethyl methylcellulose, ethyl propylcellulose or
isopropylcellulose, and butylcellulose, cellulose aralkyl ethers such as
benzyl
cellulose, cellulose cyanoalkyl ethers such as cyanoethylcellulose, cellulose
organic acid esters such as cellulose acetate butyrate, cellulose acetate,
cellulose
propionate or cellulose butyrate, and cellulose acetate propionate, ethyl
acrylate-
methyl methacrylate copolymers (trade name Eudragit NE, manufactured by Rohm
GmbH & Co. KG, Darmstadt, Germany), and aminoalkyl methacrylate copolymer
RS (trade names Eudragit RL, Eudragit RS). There are no particular limitations
on
the mean particle diameter of a water-insoluble polymer used in the present
invention, but usually the lower this mean particle diameter the better the
performance, with the mean particle diameter preferably being from 0.1 to 100
pm,
more preferably from 1 to 50 pm, particularly preferably from 3 to 15 pm, most
preferably from 5 to 15 pm. Moreover, examples of water-soluble or water-
swelling
non-pH-dependent polymeric substances include, but are not limited to,
polyethylene oxide (trade name Polyox, manufactured by Dow Chemical Company,
molecular weight 100,000 to 7,000,000), low-substituted hydroxypropyl
cellulose
(trade name L-HPC, manufactured by Shin-Etsu Chemical, Japan), hydroxypropyl
cellulose (trade name HPC, manufactured by Nippon Soda, Co., Ltd, Japan),
24
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
hydroxypropyl methylcellulose (trade names Metolose 60SH, 65SH, 90SH,
manufactured by Shin-Etsu Chemical, Japan), and methylcellulose (trade name
Metolose SM, manufactured by Shin-Etsu Chemical, Japan).
Note that in the present invention, a single non-pH-dependent polymeric
substance may be contained in the composition, or a plurality of the non-pH-
dependent polymeric substances may be contained. The non-pH-dependent
polymeric substance used in the present invention is preferably a water-
insoluble
polymeric substance, more preferably ethylcellulose, an ethyl acrylate-methyl
methacrylate copolymer (trade name Eudragit NE), or an aminoalkyl methacrylate
copolymer RS (trade name Eudragit RL, Eudragit RS). Particularly preferable is
at
least one of ethylcellulose and an aminoalkyl methacrylate copolymer RS. Most
preferable is ethylcellulose. There are no particular limitations on the
amount of the
non-pH-dependent polymeric substance contained in the composition; this amount
can be adjusted as appropriate in accordance with the purpose such as
controlling
sustained drug release.
(pH-dependent polymeric substances)
A pH-dependent polymeric substance used in the present invention is a
polymeric substance whose charge state changes under pH conditions generally
found in the gastrointestinal tract, specifically from pH 1 to pH 8. This
means, for
example, a polymeric substance having functional groups whose charge state
changes depending on the pH such as basic functional groups such as amino
groups or acidic functional groups such as carboxylic acid groups. The pH-
dependent functional groups of the pH-dependent polymeric substance are
preferably acidic functional groups, with the pH-dependent polymeric substance
most preferably having carboxylic acid groups.
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
The pH-dependent polymeric substance used in the present invention may
be water-insoluble, or may swell in water or dissolve in water to form a gel.
Examples of pH-dependent polymeric substances used in the present invention
include, but are not limited to, enteric polymeric substances. Examples of
enteric
polymeric substances include, but are not limited to, methacrylic acid-methyl
methacrylate copolymers (Eudragit L100, Eudragit S100, manufactured by ROhm
GmbH & Co. KG, Darmstadt, Germany), methacrylic acid-ethyl acrylate copolymers
(Eudragit L100-55, Eudragit L30D-55, manufactured by R6hm GmbH & Co. KG,
Darmstadt, Germany), hydroxypropyl methylcellulose phthalate (HP-55, HP-50,
manufactured by Shin-Etsu Chemical, Japan), hydroxypropyl methylcellulose
acetate succinate (AQOAT, manufactured by Shin-Etsu Chemical, Japan),
carboxymethyl ethylcellulose (CMEC, manufactured by Freund Corporation,
Japan),
and cellulose acetate phthalate. Examples of pH-dependent polymeric substances
that swell in water or dissolve in water to form a gel include, but are not
limited to,
alginic acid, pectin, carboxyvinyl polymer, and carboxymethyl cellulose. In
the
present invention, a single pH-dependent polymeric substance may be contained
in
the composition, or a plurality of pH-dependent polymeric substances may be
contained. The pH-dependent polymeric substance used in the present invention
is
preferably an enteric polymeric substance, more preferably a methacrylic acid-
ethyl
acrylate copolymer, a methacrylic acid-methyl methacrylate copolymer,
hydroxypropyl methylcellulose phthalate, or hydroxypropyl methylcellulose
acetate
succinate, particularly preferably a methacrylic acid-ethyl acrylate
copolymer.
When using a pH-dependent polymeric substance in the manufacturing
process of the composition according to the present invention, a commercially
available product of a powder type or a granular type, or a suspension type in
which the pH-dependent polymeric substance has been dispersed in a solvent in
26
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
advance can be used as is, or such a commercially available product can be
used
dispersed in water or an organic solvent. The lower the particle diameter of
the pH-
dependent polymeric substance the better the performance, with the pH-
dependent
polymeric substance preferably being of the powder type. In the case of a
methacrylic acid-ethyl acrylate copolymer, an example is Eudragit L100-55.
There
are no particular limitations on the mean particle diameter of a pH-dependent
polymeric substance used in the present invention, but the mean particle
diameter
is preferably from 0.05 to 100 pm, more preferably from 0.05 to 70 pm, most
preferably from 0.05 to 50 pm. Moreover, there are no particular limitations
on the
amount of the pH-dependent polymeric substance, for example, in the case of an
enteric polymeric substance, the amount is generally from 0.1 to 90 parts by
weight,
preferably from 1 to 70 parts by weight, more preferably from 5 to 60 parts by
weight, particularly preferably from 10 to 50 parts by weight, based on 100
parts by
weight of the composition.
(Additives)
The composition according to the present invention may further contain any
of various additives, such as any of various pharmacologically acceptable
carriers
such as diluents, lubricants, binders and disintegrants, as well as
preservatives,
colorants, sweeteners, plasticizers, film coating agents and so on, as
necessary.
Examples of diluents include, but are not limited to, lactose, mannitol,
dibasic
calcium phosphate, starch, pregelatinized starch, crystalline cellulose, light
silicic
anhydride, synthetic aluminum silicate, magnesium aluminate metasilicate or
the
like. Examples of lubricants include, but are not limited to, magnesium
stearate,
calcium stearate, talc, sodium stearyl fumarate or the like. Examples of
binders
include, but are not limited to, hydroxypropyl cellulose, methylcellulose,
sodium
27
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
carboxymethyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone
or the
like. Examples of disintegrants include, but are not limited to, carboxymethyl
cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium
carboxymethyl starch, low-substituted hydroxypropyl cellulose or the like.
Examples of preservatives include, but are not limited to, paraoxybenzoic acid
esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid,
sorbic
acid or the like. Preferable examples of colorants include, but are not
limited to,
water-insoluble lake pigments, natural pigments (e.g. p-carotene, chlorophyll,
red
ferric oxide), yellow ferric oxide, red ferric oxide, black ferric oxide or
the like.
Preferable examples of sweeteners include, but are not limited to, sodium
saccharin, dipotassium glycyrrhizate, aspartame, stevia or the like. Examples
of
plasticizers include, but are not limited to, glycerol fatty acid esters,
triethyl citrate,
propylene glycol, polyethylene glycol or the like. Examples of film coating
agents
include, but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl
cellulose or the like.
(Manufacturing methods)
To manufacture the composition according to the present invention, a single
conventional method, or a combination of conventional methods, can be used.
For
example, when manufacturing anti-dementia drug-containing granules as a
sustained-release portion or a quick-release portion in the present invention,
granulation is the main operation, but this may be combined with other
operations
such as mixing, drying, sieving, and classification. As the granulation
method, for
example, a wet granulation method in which a binder and a solvent are added to
the powder and granulation is carried out, a dry granulation method in which
the
powder is compressed and granulation is carried out, a molten granulation
method
28
CA 02604617 2012-09-25
. .
in which a binder that melts on heating is added and heating and granulation
are
carried out, or the like can be used. Furthermore, in accordance with the
granulation method, an operating method such as a mixing granulation method
using a planetary mixer, a screw mixer or the like, a high-speed mixing
granulation
method using a Henschel mixerra Super mixer or the like, an extruding
granulation
method using a cylindrical granulator, a rotary granulator, a screw extruding
granulator, a pellet mill type granulator or the like, a wet high-shear
granulation
method, a fluidized-bed granulation method, a compression granulation method,
a
crushing granulation method, or a spraying granulation method can be used.
After
the granulation, drying using a dryer, a fluidized bed or the like, cracking,
and
sieving can be carried out to obtain the granules or fine granules for use.
Moreover,
a granulation solvent may be used when preparing the composition according to
the present invention. There are no particular limitations on such a
granulation
solvent, which may be water or any of various organic solvents, for example,
water,
a lower alcohol such as methanol or ethanol, a ketone such as acetone or
methyl
ethyl ketone, methylene chloride, or a mixture thereof.
(Method of manufacturing granules)
For sustained-release granules contained in the composition according to
the present invention, at least one anti-dementia drug and at least one
selected
from non-pH-dependent polymeric substances and pH-dependent polymeric
substances are mixed together, a diluent and a binder are added as necessary,
and granulation is carried out to obtain granular matter. The granular matter
obtained is dried using a tray dryer, a fluidized bed dryer or the like, and
sieving is
carried out using a mill or an oscillator, whereby the sustained-release
granules can
be obtained. Alternatively, as a method of manufacturing sustained-release
29
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
granules in the present invention, it is possible to add at least one anti-
dementia
drug, at least one selected from non-pH-dependent polymeric substances and pH-
dependent polymeric substances, and as necessary a diluent and a binder using
a
dry compactor such as a roller compactor or a slug tabletting machine, and
carry
out compression-molding while mixing, and then carry out granulation by
cracking
down to a suitable size. The granular matter prepared using such a granulator
may
be used as is as granules or fine granules according to the present invention,
or
may be further cracked using a power mill, a roll granulator, a rotor speed
mill or
the like, and sieved to obtain sustained-release granules. Note that quick-
release
granules can also be manufactured as for the sustained-release granules.
(Method of manufacturing compression-molded product)
A compression-molded product can be manufactured as an anti-dementia
drug-containing sustained-release portion or quick-release portion, or as the
composition according to the present invention using a single conventional
method,
or a combination of conventional methods. For example, at least one anti-
dementia
drug, at least one selected from non-pH-dependent polymeric substances and pH-
dependent polymeric substances, a diluent such as mannitol or lactose, a
binder
such as polyvinylpyrrolidone or crystalline cellulose, a disintegrant such as
carmellose sodium or crospovidone, and a lubricant such as magnesium stearate
or talc are used, and tableting is carried out using an ordinary method,
whereby the
compression-molded product can be obtained. In this case, tabletting is the
main
operation in the method of manufacturing the compression-molded product, but
this
may be combined with other operations such as mixing, drying, sugar coating
formation, and coating. Examples of the method for the tabletting include, but
are
not limited to, direct compression molding in which at least one anti-dementia
drug
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
and pharmacologically acceptable additives are mixed together and then the
mixture is directly compression-molded into tablets using a tabletting
machine, and
dry granule compression or wet granule compression in which sustained-release
granules or quick-release granules according to the present invention are
subjected
to compression-molding after adding a lubricant or a disintegrant as
necessary.
There are no particular limitations on the tabletting machine used in the
compression molding; for example, a single-punch tabletting machine, a rotary
tabletting machine, or a press-coated tabletting machine can be used.
(Coating method)
The anti-dementia drug-containing sustained-release granules or quick-
release granules, or compression-molded product according to the present
invention can be used as is in the form of granules or a tablet as the
composition of
the present invention, but may also be subjected to further processing to
manufacture the composition. For example, the compression-molded product or
granules can be given a film coating using a film base material such as
ethylcellulose, casein, methylcellulose, hydroxypropyl methylcellulose,
methacrylic
acid copolymer L, cellulose acetate phthalate, shellac or the like, or given a
sugar
coating using a sugar coating liquid containing saccharose, sugar alcohol, gum
arabic powder, talc or the like, thus producing film-coated tablets or sugar-
coated
tablets. A preferable solvent in this coating technique is purified water, but
an
organic solvent such as an alcohol, a ketone, an ether or a chlorinated
hydrocarbon,
or a mixture thereof can also be used. For example, ethanol, acetone,
methylene
chloride or the like can be used as an organic solvent. Moreover, as the
coating
apparatus, an apparatus ordinarily used in coating techniques for
manufacturing
medicines can be used, with examples including a spray coating apparatus in
31
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
which the coating is carried out by spraying a coating liquid or the like, and
a rotor
fluidized bed granulator for layering.
(Other manufacturing methods)
In the case of manufacturing capsule preparations, the capsule preparations
can be manufactured by filling sustained-release granules or quick-release
granules as above, or mini-tablets into hard gelatin capsules or HPMC capsules
using an automatic capsule filling machine. Alternatively, in the case of the
preparations for per-tube administration or a dry syrup that is used mixed
with
water or the like when taken, sustained-release granules or quick-release
granules
as above can be mixed with a thickener or a dispersant so as to disperse these
granules, the mixture then being made into granules or tablets. Furthermore, a
liquid or jelly can be made using water, and substances selected from
dispersants,
emulsifiers, thickeners, preservatives, pH adjustors, sweeteners, flavorings,
fragrances and so on. However, with respect to other manufacturing methods,
there are no limitations to the above.
(Dissolution test)
With the composition of the present invention, release of the anti-dementia
drugs can be controlled. A dissolution test method described in the Japanese
Pharmacopoeia 14th Edition, USP or the like can be used for identifying a
means of
controlled release of the anti-dementia drugs, or for evaluating the state of
controlled release. For example, measurement can be carried out using the
first
dissolution test method (rotating basket method), the second dissolution test
method (paddle method), or the third dissolution test method (flow-through
cell
method) in the Japanese Pharmacopoeia. A composition with specified
dissolution
32
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
profile according to the present invention can be obtained using such a test
method.
For example, according to the present invention, a composition can be obtained
in
which, for each of two anti-dementia drugs contained in the composition, in a
dissolution test, dissolution with little pH dependence can be secured during
an
early stage of dissolution, and then in a late stage of dissolution,
proportion of the
dissolution ratio in an acidic solution to the dissolution ratio in a neutral
solution
decreases over time as the dissolution test proceeds.
As a dissolution test solution, assuming gastric juice or intestinal juice, an
aqueous solution of pH in a range of 1 to 9 can be used. For example, a buffer
such as a phosphate buffer (e.g. a buffer prepared from a 50 mM sodium
phosphate aqueous solution and hydrochloric acid), G.L. Miller buffer, Atkins-
Pantin
buffer, or Good buffer, or a 0.1 N hydrochloric acid solution, or a 0.1 mol/L
sodium
hydroxide solution, or the like can be used. The dissolution ratio is
calculated by
measuring the drug concentration at intervals of 15 minutes, 30 minutes, 1
hour, or
2 hours. Regarding the test period in the dissolution test, measurement is
carried
out until the dissolution ratio reaches at least 85%, or in the case of an
acidic
dissolution test solution, for at least 2 hours, or in the case of a neutral
or basic
dissolution test solution, for at least 24 hours.
(Controlled-release composition)
The composition according to the present invention contains at least two
kinds of anti-dementia drugs, with it being possible to control the
dissolution of
these anti-dementia drugs together or individually. For example, the present
invention provides a composition, upon carrying out measurement using the
second dissolution test method in the Japanese Pharmacopoeia with a paddle
rate
of 50 rpm, in which at least one anti-dementia drug contained in the
composition
33
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
has a dissolution ratio in a 0.1 N hydrochloric acid solution of pH 1 being
from 20 to
50% at a dissolution time of 1 hour, and being from 85 to 100% at a
dissolution
time of 3 hours. Moreover, the composition may be such that, under the same
dissolution conditions, at least one anti-dementia drug contained in the
composition
has a dissolution ratio in a 0.1 N hydrochloric acid aqueous solution of pH 1
being
from 5 to 20% at a dissolution time of 1 hour, and being from 90 to 100% at a
dissolution time of 8 hours. By combining such dissolution characteristics,
the anti-
dementia drugs contained in the composition according to the present invention
can thus all be made to be sustained-release or quick-release. Alternatively,
one of
the anti-dementia drugs can be made to be quick-release, and the remainder
sustained-release.
(Dissolution profiles)
According to the present invention, there can be provided, as a composition
in which two kinds of anti-dementia drugs are made to be sustained-release, a
composition specified by the dissolution profiles in a neutral (e.g. pH 6 to
8)
dissolution test solution. Specifically, a composition in which, under the
Japanese
Pharmacopoeia paddle dissolution test method, the dissolution ratio for each
of
donepezil hydrochloride and memantine hydrochloride in a dissolution test
solution
of pH 6 to 8 is less than 60% at a dissolution time of 1 hour, and not less
than 80%
at a dissolution time of 8 hours. To delay the dissolution of these drugs, the
dissolution ratio for each of donepezil hydrochloride and memantine
hydrochloride
is preferably less than 50%, more preferably less than 40%, at a dissolution
time of
1 hour.
Moreover, according to the present invention, there can be provided a
composition in which donepezil hydrochloride is released at an early stage in
an
34
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
acidic region (e.g. pH 1 to 3), and memantine hydrochloride is released at a
late
stage in a neutral region (e.g. pH 6 to 8). For example, there can be provided
a
composition in which, under the Japanese Pharmacopoeia paddle dissolution test
method, the dissolution ratio for donepezil hydrochloride in a dissolution
test
solution of pH 1 to 2 is not less than 60% at a dissolution time of 1 hour,
and the
dissolution ratio for memantine hydrochloride in a dissolution test solution
of pH 6
to 8 is less than 60% at a dissolution time of 1 hour and at not less than 80%
at a
dissolution time of 8 hours.
To accelerate the dissolution of donepezil hydrochloride, the dissolution
ratio
for donepezil hydrochloride is preferably not less than 80%, more preferably
not
less than 85%, at a dissolution time of 1 hour. Moreover, to delay the
dissolution
of memantine hydrochloride, the dissolution ratio for memantine hydrochloride
is
preferably less than 50%, more preferably less than 40%, at a dissolution time
of 1
hour.
Furthermore, according to the present invention, there can be provided a
composition in which memantine hydrochloride is released at an early stage in
an
acidic region, and donepezil hydrochloride is released at a late stage in a
neutral
region. For example, there can be provided a composition in which, under the
Japanese Pharmacopoeia paddle dissolution test method, the dissolution ratio
for
memantine hydrochloride in a dissolution test solution of pH 1 to 2 is not
less than
60% at a dissolution time of 1 hour, and the dissolution ratio for donepezil
hydrochloride in a dissolution test solution of pH 6 to 8 is less than 60% at
a
dissolution time of 1 hour and not less than 80% at a dissolution time of 8
hours.
To accelerate the dissolution of memantine hydrochloride, the dissolution
ratio for memantine hydrochloride is preferably not less than 80%, more
preferably
not less than 85%, at a dissolution time of 1 hour. Moreover, to delay the
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dissolution of donepezil hydrochloride, the dissolution ratio for donepezil
hydrochloride is preferably less than 50%, more preferably less than 40%, at a
dissolution time of 1 hour.
Furthermore, according to the present invention, there can be provided a
composition in which both donepezil hydrochloride and memantine hydrochloride
are released at an early stage in an acidic region. For example, there can be
provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method, the dissolution ratio for each of donepezil
hydrochloride
and memantine hydrochloride in a dissolution test solution of pH 1 to 2 is not
less
than 60%, preferably not less than 80%, more preferably not less than 85%, at
a
dissolution time of 1 hour.
(Proportion of dissolution ratios)
According to the present invention, there can be provided a composition in
which dissolution profiles for donepezil hydrochloride and memantine
hydrochloride
are similar to or the same as one another. By making the dissolution
characteristics be similar, a synergistic effect between the two drugs can be
expected. For example, there can be provided a composition in which, for the
dissolution ratios in the same dissolution test solution using the Japanese
Pharmacopoeia paddle dissolution test method, the proportion of the
dissolution
ratio for memantine hydrochloride to the dissolution ratio for donepezil
hydrochloride is in a range of 1 0.3 at not less than three dissolution time
points.
Furthermore, to make the dissolution characteristics of the two anti-dementia
drugs
be similar to one another, this proportion of the dissolution ratios is
preferably in a
range of 1 0.2, more preferably 1 0.15.
36
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
Note that "the same dissolution test solution" refers to dissolution test
solutions having the same composition and the same pH.
Moreover, the three or more dissolution time points at which the dissolution
ratios are compared can be selected as desired. Specifically, in the case of
assuming dissolution in the stomach and thus using an aqueous solution of pH 1
to
2 as the test solution, a plurality of dissolution time points between 15
minutes and
4 hours can be selected. Moreover, in the case of assuming dissolution in the
intestines and thus using an aqueous solution of pH 6 to 8, a plurality of
dissolution
time points between 6 and 10 hours can be selected. For example, there can be
provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method using a dissolution test solution of pH 6 to 8, the
proportion
of the dissolution ratio for memantine hydrochloride to the dissolution ratio
for
donepezil hydrochloride is in a range of 1 0.3 for each of the dissolution
times 1
hour, 4 hours, and 8 hours.
Furthermore, there can be provided a composition in which the dissolution
profiles at a late stage of dissolution are similar to or the same as one
another. For
example, there can be provided a composition in which, under the Japanese
Pharmacopoeia paddle dissolution test method using a dissolution test solution
of
pH 6 to 8, the proportion of the dissolution ratio for memantine hydrochloride
to the
dissolution ratio for donepezil hydrochloride is in a range of 1 0.3 for
each of the
dissolution times 6 hours, 8 hours, and 10 hours.
Furthermore, there can be provided a composition in which the dissolution
profiles at an early stage of dissolution are similar to or the same as one
another.
For example, there can be provided a composition in which, under the Japanese
Pharmacopoeia paddle dissolution test method using a dissolution test solution
of
pH 1 to 2, the proportion of the dissolution ratio for memantine hydrochloride
to the
37
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dissolution ratio for donepezil hydrochloride is in a range of 1 0.3 for
each of the
dissolution times 15 minutes, 30 minutes, and 45 minutes.
Moreover, there can be provided a composition in which the dissolution
profiles are made to be similar to one another up to a dissolution time of 3
hours in
an acidic dissolution test solution, and are made to be similar to one another
over a
dissolution time range of 4 to 8 hours in a neutral dissolution test solution.
As the dissolution time points at which the dissolution ratios are compared,
dissolution times at which the dissolution ratio for one of the anti-dementia
drugs
reaches 30%, 50%, and 80% can be selected as desired. Specifically, there can
be provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method using a dissolution test solution of pH 6 to 8, the
proportion
of the dissolution ratio for memantine hydrochloride to the dissolution ratio
for
donepezil hydrochloride is in a range of 1 0.3 for each of the dissolution
times at
which the dissolution ratio for one of the anti-dementia drugs is 30 5%, 50
5%,
and 80 5%.
Moreover, as the dissolution time points at which the dissolution ratios are
compared, the dissolution time at which the dissolution ratio reaches
approximately
85% in the dissolution test can be selected together with 1/4, 1/2, and 3/4 of
this
dissolution time.
Specifically, there can be provided a composition in which, under the
Japanese Pharmacopoeia paddle dissolution test method using a dissolution test
solution of pH 6 to 8, the proportion of the dissolution ratio for memantine
hydrochloride to the dissolution ratio for donepezil hydrochloride is in a
range of 1
0.3 for each of the dissolution time at which the dissolution ratio for
donepezil
hydrochloride reaches 85 5%, and 1/4, 1/2, and 3/4 of this dissolution time.
38
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
(f2 function)
The composition according to the present invention can be specified by a f2
function value (similarity factor) calculated from the dissolution ratios in
an in vitro
dissolution test. For example, according to the present invention, there can
be
provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method, the f2 function value for the donepezil hydrochloride
and
memantine hydrochloride dissolution profiles is in a range of 42 to 100, i.e.
a
composition in which the dissolution profiles for the two kinds of anti-
dementia
drugs are similar to one another. The f2 function value is preferably in a
range of
from 50 to 100, more preferably from 60 to 100. Note that, in general, the
closer
the f2 function value is to 100, the more similar are the two dissolution
profiles being
compared, and if the f2 function value is not less than 50, then it is
considered that
the two dissolution profiles being compared are "equivalent".
Here, the f2 function is calculated using the following formula.
100
f2 = 50 log _______________________________________________________
/ \1/(Di-Ri)2
i=1
.111 11=1111.
wherein Di and Ri are the dissolution ratios for the respective anti-dementia
drugs, and n is the number of dissolution time points at which the dissolution
ratios
are compared.
39
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
Note that in the case that the dissolution ratio for one of the anti-dementia
drugs reaches not less than 85% in less than 30 minutes, the dissolution time
points at which the dissolution ratios are compared are taken to be 15
minutes, 30
minutes, and 45 minutes (n = 3). Moreover, in the case that the dissolution
time at
which the dissolution ratio reaches not less than 85% is greater than 30
minutes for
one of the anti-dementia drugs, taking a specified dissolution time at which
the
dissolution ratio reaches not less than 80% (hereinafter referred to as "T")
as a
standard time, the dissolution time points at which the dissolution ratios are
compared are taken to be 1/4 T, 1/2 T, 3/4 T, and T (n = 4).
According to the present invention, there can also be provided a composition
in which the dissolution in an acidic dissolution test solution and the
dissolution in a
neutral dissolution test solution are equivalent to one another for each of
the at
least two kinds of anti-dementia drugs. According to such a composition, the
risk of
the blood concentration of the drugs varying upon the gastric emptying time
changing can be reduced. For example, in the present invention, there can be
provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method, for dissolution times of 2 hours onwards, the
proportion of
the dissolution ratio in an acidic dissolution test solution to the
dissolution ratio in a
neutral dissolution test solution for donepezil hydrochloride is in a range of
1 0.3,
and the proportion of the dissolution ratio in an acidic dissolution test
solution to the
dissolution ratio in a neutral dissolution test solution for memantine
hydrochloride is
in a range of 1 0.3. In this case, the proportion of the dissolution ratios
is
preferably in a range of 1 0.2, more preferably 1 0.15.
Specifying in terms of the f2 function value, for example, there can be
provided a composition in which, under the Japanese Pharmacopoeia paddle
dissolution test method, the f2 function value for the acidic dissolution test
solution
CA 02604617 2007-10-12
Our Ref: E0006 UP31W/KAN
and neutral dissolution test solution dissolution profiles for donepezil
hydrochloride
is in a range of from 42 to 100, and moreover the f2 function value for the
acidic
dissolution test solution and neutral dissolution test solution dissolution
profiles for
memantine hydrochloride is in a range of from 42 to 100. In this case, at
least one
of the f2 function value for donepezil hydrochloride and the f2 function value
for
memantine hydrochloride is preferably in a range of from 50 to 100, more
preferably from 60 to 100.
Note that a dissolution test solution of pH 1 to 2 can be used as the acidic
dissolution test solution, and a dissolution test solution of pH 6 to 8 can be
lAed as
the neutral dissolution test solution.
Techniques for making the release be sustained can be used, in particular,
to solve problems of compliance for the patient taking the anti-dementia
drugs. For
example, the present invention provides a composition, upon carrying out
measurement using the second dissolution test method in the Japanese
Pharmacopoeia with a paddle rate of 50 rpm, in which at least one anti-
dementia
drug contained in the composition has a proportion of the dissolution ratio
for the
anti-dementia drug in a 0.1 N hydrochloric solution, pH 1 to the dissolution
ratio for
the anti-dementia drug in a 50 mM phosphate buffer, pH 6.8 at a dissolution
time of
3 hours of from 0.3 to 1.3. That is, the dissolution ratio while residing in
the
stomach is suppressed, or the speed of dissolution is made low, whereby the
drug
concentration in the blood plasma can be prevented from rising suddenly. The
occurrence of side effects can thus be prevented, and there is a contribution
to
making the drug release sustained.
In another example, the present invention provides a composition, upon
carrying out measurement using the second dissolution test method in the
Japanese Pharmacopoeia with a paddle rate of 50 rpm, in which at least one
anti-
41
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dementia drug contained in the composition has a proportion of the dissolution
ratio
for the anti-dementia drug in a 0.1 N hydrochloric acid solution, pH 1 to the
dissolution ratio for the anti-dementia drug in a 50 mM phosphate buffer, pH
6.8
that decreases with dissolution time up to the dissolution time at which the
dissolution ratio in the 50 mM phosphate buffer, pH 6.8 is 90%. That is, the
dissolution ratio in the stomach is kept low, and furthermore a decrease in
the drug
bioavailability as the composition passes from the stomach into the small
intestine
is inhibited, and hence the pharmacological effects can be achieved reliably.
With the composition acbording to the present invention, the release of a
plurality of anti-dementia drugs can be controlled simultaneously in a single
composition. For example, in the case of a composition containing two drugs
having different solubilities to one another at pH 6.8, by producing a two-
layer tablet
formed from a first layer containing the less soluble anti-dementia drug and a
second layer containing the more soluble anti-dementia drug, and making the
total
amount of non-pH-dependent polymeric substances and pH-dependent polymeric
substances added as release-controlling substances be higher in the second
layer
than in the first layer, a desired sustained-release preparation can be
obtained.
As another example, in the case of a composition containing two drugs
having different solubility ratios between in a 0.1 N hydrochloric acid
solution, pH 1
and in a 50 mM phosphate buffer, pH 6.8 (i.e. solubility in the 0.1 N
hydrochloric
acid solution, pH 1 / solubility in the 50 mM phosphate buffer, pH 6.8), by
producing
a two-layer tablet formed from a first layer containing the anti-dementia drug
having
the lower solubility ratio and a second layer containing the anti-dementia
drug
having the higher solubility ratio, and making the amount of pH-dependent
polymeric substances based on 1 part by weight of non-pH-dependent polymeric
substances be higher in the second layer than in the first layer, a desired
42
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
sustained-release preparation can be obtained. Furthermore, as still another
example, for two drugs having both (1) a different solubility in a 50 mM
phosphate
buffer, pH 6.8 and (2) .a different solubility ratio between in a 0.1 N
hydrochloric
acid solution, pH 1 and in a 50 mM phosphate buffer, pH 6.8, by suitably
adjusting
both the total amount of non-pH-dependent polymeric substances and pH-
dependent polymeric substances added as release-controlling substances, and
the
amount of the pH-dependent polymeric substances relative to the non-pH-
dependent polymeric substances as in the above examples, a desired sustained-
release preparation can be obtained. =
In a preferable aspect of the present invention, there is provided a
composition in which memantine hydrochloride and donepezil hydrochloride are
contained in the same sustained-release portion or quick-release portion. This
is
advantageous in terms of production efficiency and cost, since the at least
two
kinds of anti-dementia drugs can be controlled such as to have dissolution
profiles
as described above, and moreover both are in a single formulation. An example
is
a matrix type preparation containing donepezil hydrochloride and memantine
hydrochloride as the anti-dementia drugs, containing non-pH-dependent
polymeric
substances and pH-dependent polymeric substances as release-controlling
substances, and further containing pharmacologically acceptable additives. The
matrix type preparation is preferably a tablet, a capsule preparation,
granules, fine
granules, or an orally rapid disintegrating tablet. Moreover, preferable
release-
controlling substances are ethylcellulose and a methacrylic acid-ethyl
acrylate
copolymer. Moreover, the matrix type preparation can be manufactured using a
manufacturing method including a mixing step of mixing the anti-dementia
drugs,
the release-controlling substances and the pharmacologically acceptable
additives
together, and as necessary a granulation step of adding a binder to the
mixture and
43
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
granulating. In the case of a tablet or an orally rapid disintegrating tablet,
this can
be manufactured using a manufacturing method including a compression-molding
step of compression molding the mixture obtained in the mixing step or the
granular
matter obtained in the granulation step. Furthermore, the manufacturing method
may contain a step of coating the compression-molded product. Moreover, the
granular matter obtained in the granulation step may be used as is as granules
or
fine granules, but the manufacture may also be carried out using a
manufacturing
method further including a step of mixing the granular matter with
pharmacologically acceptable additives. A capsule preparation can be
manufactured through a step of filling the granular matter obtained in the
granulation step, or the granules or fine granules into a capsule.
In the present invention, regardless of whether the composition contains one
sustained-release portion or a plurality of sustained-release portions, the
content of
release-controlling substances (non-pH-dependent polymeric substances and pH-
dependent polymeric substances) in each sustained-release portion is generally
from 1 to 99%, preferably from 5 to 90%, more preferably from 10 to 80%.
Similarly,
in the present invention, the content of the pH-dependent polymeric substances
based on 1 part by weight of the non-pH-dependent polymeric substances in each
sustained-release portion is generally from 0.1 to 20 parts by weight,
preferably
from 0.2 to 10 parts by weight, more preferably from 0.3 to 5 parts by weight.
The composition according to the present invention is, of course, not limited
to the above. The composition according to the present invention is a
composition
in which dissolution control can be realized so as to achieve the effects of
the anti-
dementia drugs additively or synergistically, or so as to prevent or suppress
the
occurrence of side effects, or with some other objective, this being in
accordance
44
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
with the structural characteristics and physicochemical characteristics of the
anti-
dementia drugs.
Examples
The present invention is explained below in more detail with reference to the
following examples, but the present invention should not be construed as being
limited thereto. The additives used in the pharmaceutical compositions were
reagents, or additives complying with official documents such as the Japanese
Pharmacopoeia 14th Edition, Japanese Pharmaceutical Excipients 2003 (JPE), and
the Japan Pharmaceutical Codex 1997 (JPC).
Example 1
6 g of donepezil hydrochloride (Eisai Co. Ltd.), 12 g of memantine
hydrochloride (Lachema s.r.o.), 28.8 g of Ethocel 10FP (ethylcellulose, Dow
Chemical Company), 36 g of Eudragit L100-55 (R6hm GmbH & Co. KG), and 45.6
g of lactose were mixed together in a granulator. An aqueous solution of 2.4 g
of
hydroxypropyl cellulose in a suitable amount of purified water was added to
the
mixture and wet granulation was carried out, and then the granules thus
obtained
were heat dried using a tray dryer, and then sieved to obtain the desired
granule
size. After sieving, 1 g of magnesium stearate based on 109 g of the granules
was
added and mixed in, and then a rotary tabletting machine was used to form
tablets,
whereby a compression-molded product with diameter 8 mm containing 10 mg of
donepezil hydrochloride and 20 mg of memantine hydrochloride in a 220 mg
tablet
was obtained. Opadry yellow (Colorcon Japan Limited) was used to give the
resulting product a water-soluble film coating containing hydroxypropyl
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
methylcellulose as its main component (coating amount: 8 mg/tablet), resulting
in
film-coated tablets.
Example 2
5 g of donepezil hydrochloride (Eisai Co. Ltd.), 10 g of memantine
hydrochloride (Lachema s.r.o.), 20 g of corn starch (Nihon Shokuhin Kako Co.,
Ltd.), 15 g of crystalline cellulose (Asahi Kasei Corporation), and 81.75 g of
lactose
were mixed together in a granulator. An aqueous solution of 3.0 g of
hydroxypropyl
cellulose in a suitable amount of purified water was added to the mixture and
wet
granulation was carried out, and then the granules thus obtained were heat
dried
using a tray dryer, and then sieved to obtain the desired granule size. After
the
sizing, 0.25 g of magnesium stearate based on 134.75 g of the granules was
added
and mixed in, and then a rotary tabletting machine was used to form tablets,
whereby a compression-molded product with diameter 7 mm containing 5 mg of
donepezil hydrochloride and 10 mg of memantine hydrochloride in a 135 mg
tablet
was obtained. Opadry yellow (Colorcon Japan Limited) was used to give the
resulting product a water-soluble film coating containing hydroxypropyl
methylcellulose as its main component (coating amount: 5 mg / tablet),
resulting in
film-coated tablets.
Example 3
12 g of memantine hydrochloride (Lachema s.r.o.), 28.8 g of Ethocel 10FP
(ethylcellulose, Dow Chemical Company), 36 g of Eudragit L100-55 (Rstihm GmbH
& Co. KG), and 39.6 g of lactose were mixed together in a granulator. An
aqueous
solution of 2.4 g of hydroxypropyl cellulose in a suitable amount of purified
water
was added to the mixture and wet granulation was carried out, and then the
46
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
granules thus obtained were heat dried using a tray dryer, and then sieved to
obtain the desired granule size. After sieving, 1 g of magnesium stearate
based on
99 g of the granules was added and mixed in, and then a rotary tabletting
machine
was used to form tablets, whereby a compression-molded product with diameter 8
mm containing 20 mg of memantine hydrochloride in a 200 mg tablet was
obtained.
On the other hand, 3 g of donepezil hydrochloride (Eisai Co. Ltd.), 19.2 g of
corn
starch (Nihon Shokuhin Kako Co., Ltd.), 14.4 g of crystalline cellulose (Asahi
Kasei
Corporation), and 89.88 g of lactose were mixed together in a granulator. An
aqueoLis solution of 2.88 g of hydroxypropyl cellulose in a Suitable amount of
purified water was added to the mixture and wet granulation was carried out,
and
then the granules thus obtained were heat dried using a tray dryer, and then
sieved
to obtain the desired granule size. After sieving, 0.4 g of magnesium stearate
based on 215.6 g of the granules was added and mixed in, whereby a mixture
containing donepezil hydrochloride was obtained. Subsequently, using 216 mg of
the mixture containing donepezil hydrochloride per tablet of the compression-
molded product containing memantine hydrochloride, a press-coated tabletting
machine was used to form tablets, whereby press-coated tablets comprising an
outer layer containing 5 mg of donepezil hydrochloride and an inner core layer
containing 20 mg of memantine hydrochloride in a 416 mg tablet were obtained.
Example 4
6 g of donepezil hydrochloride (Eisai Co. Ltd.), 28.8 g of Ethocel 10FP
(ethylcellulose, Dow Chemical Company), 36 g of Eudragit L100-55 (Rohm GmbH
& Co. KG), and 57.6 g of lactose were mixed together in a granulator. An
aqueous
solution of 2.4 g of hydroxypropyl cellulose in a suitable amount of purified
water
was added to the mixture and wet granulation was carried out, and then the
47
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
granules thus obtained were heat dried using a tray dryer, and then sieved to
obtain the desired granule size. After sieving, 1 g of magnesium stearate
based on
99 g of the granules was added and mixed in, and then a rotary tableting
machine
was used to form tablets, whereby a compression-molded product with diameter 8
mm containing 10 mg of donepezil hydrochloride in a 200 mg tablet was
obtained.
On the other hand, 6 g of memantine hydrochloride (Lachema s.r.o.), 19.2 g of
corn
starch (Nihon Shokuhin Kako Co., Ltd.), 14.4 g of crystalline cellulose (Asahi
Kasei
Corporation), and 86.88 g of lactose were mixed together in a granulator. An
aqueous solution of 2.88 g of hydroxypropyl cellulose in a suitable amount of
purified water was added to the mixture and wet granulation was carried out,
and
then the granules thus obtained were heat dried using a tray dryer, and then
sieved
to obtain the desired granule size. After sieving, 0.4 g of magnesium stearate
based on 215.6 g of the granules was added and mixed in, whereby a mixture
containing memantine hydrochloride was obtained. Subsequently, using 216 mg of
the mixture containing memantine hydrochloride per tablet of the compression-
molded product containing donepezil hydrochloride, a press-coated tableting
machine was used to form tablets, whereby press-coated tablets comprising an
outer layer containing 10 mg of memantine hydrochloride and an inner core
layer
containing 10 mg of donepezil hydrochloride in a 416 mg tablet were obtained.
Example 5
6 g of donepezil hydrochloride (Eisai Co. Ltd.), 12 g of memantine
hydrochloride (Lachema s.r.o.), 30 g of Ethocel 10FP (ethylcellulose, Dow
Chemical Company), 18 g of Eudragit L100-55 (ROhm GmbH & Co. KG), and 50.04
g of lactose (trade name Pharamatose 200M, DMV Japan) were mixed together in
a granulator. An aqueous solution of 3.6 g of hydroxypropyl cellulose (trade
name
48
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
HPC-L, Nippon Soda, Co., Ltd, Japan) in a suitable amount of purified water
was
added to the mixture and wet granulation was carried out. The granules thus
obtained were then heat dried using a tray dryer, and then sieved to obtain
the
desired granule size. After sieving, 0.36 g of magnesium stearate based on
119.64
g of the granules was added and mixed in, and then a single-punch tabletting
machine was used to form tablets, whereby a compression-molded product with
diameter 8 mm containing 10 mg of donepezil hydrochloride and 20 mg of
memantine hydrochloride in a 200 mg tablet was obtained.
Examples 6 to 9
Compression-molded products were obtained using the same method as in
Example 5. The mixing proportions of the components were as shown in FIG. 1.
(Dissolution tests)
Dissolution tests were carried out using the compression-molded products
obtained in the examples. Each dissolution test was carried out in accordance
with
the dissolution test method described in the Japanese Pharmacopoeia 14th
Edition,
using test solution A indicated below as an acidic test solution, and test
solution B
indicated below as a neutral test solution, with a paddle rate of 50 rpm.
Test solution A: 0.1 N hydrochloric acid solution (exhibiting pH of 1 to 2)
Test solution B: 50 mM phosphate buffer of pH 6.8 (buffer of 50 mM sodium
phosphate solution adjusted to pH 6.75 to 6.84 with hydrochloric acid)
<Measurement for donepezil hydrochloride>
For the donepezil hydrochloride dissolution ratio, the donepezil
hydrochloride concentration in each of sample solutions collected over time
was
calculated using spectrophotometric method or HPLC analysis. The
49
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
spectrophotometric method was carried out under measurement conditions of a
measurement wavelength at 315 nm and a reference wavelength at 650 nm. On
the other hand, the HPLC analysis was carried out under the following
measurement conditions: measurement column: Capcell Pak UG120 C18
(Shiseido), mobile phase: 0.1% formic acid / acetonitrile = 82 / 18 mixture,
detection
wavelength: 230 nm.
<Measurement for memantine hydrochloride>
The memantine hydrochloride dissolution ratio was determined by
calculating the memantine hydrochloride concentration in each of sample
solutions
collected over time using HPLC analysis after memantine hydrochloride was
fluorescent labeled by Fluorescamine.
The conditions for fluorescence labeling and HPLC analysis are typically as
follows: After sample solutions (1 mL) collected over time was mixed with
borate
buffer (9 mL), pH 9.0 (USP), an acetone solution (5 mL) containing
Fluorescamine
(1.2 mg/mL) was added and stirred enough. Water (10 mL) was also added into
the above solution and mixed to obtain a test sample. The test sample was
analyzed by HPLC. HPLC analysis was performed under measurement conditions;
measurement column: CAPCELL PAK UG120 C18 (Shiseido) or a equivalent
column, column temperature: 40 C, mobile phase: borate buffer, pH 9.0 (USP) /
acetonitrile = 60 / 40 mixture; and detection conditions: fluorescence
detector
(excitation wavelength / detection wavelength = 391nm / 474nm).
(Evaluation of film-coated tablets)
Evaluation results for the film-coated tablets of Example 1 and Example 2
are shown in FIG. 2. For Example 1, donepezil hydrochloride and memantine
hydrochloride both exhibited a sustained-release profile. For both drugs, the
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
dissolution ratios in solution B was less than 30% at a dissolution time of 1
hour,
and greater than 85% at a dissolution time of 8 hours. For Example 2, the
dissolution ratios for both donepezil hydrochloride and memantine
hydrochloride
showed quick-release. For both drugs, the dissolution ratio at a dissolution
time of
1 hour was greater than 85%.
(Evaluation of compression-molded products)
Dissolution tests were carried out using the compression-molded products of
Examples 5 to 8. The results of diSsolution ratios versus dissolution time are
shown in FIG. 3. It was confirmed that by changing the content of
ethylcellulose or
Eudragit, compositions having various types of dissolution profiles for
memantine
hydrochloride and donepezil hydrochloride could be obtained.
(Similarity of dissolution profiles between drugs)
A proportion of the dissolution ratio for memantine hydrochloride to the
dissolution ratio for donepezil hydrochloride (shown as "proportion of
dissolution
ratios (Mema / Done)" in table) is shown in FIG. 3. For example, for Example
6, it
was confirmed that a composition was obtained in which the proportion of the
dissolution ratios in solution A was in a range of 1 0.3 at almost all
dissolution
times throughout the dissolution test, and the proportion of the dissolution
ratios in
solution B was 1 0.3 in a late stage of dissolution from a dissolution time
of 6
hours onwards. Moreover, for Example 7, the proportion of the dissolution
ratios
for donepezil hydrochloride and memantine hydrochloride in solution B was in a
range of 1 0.3 at dissolution times of 3 hours and beyond, showing that
donepezil
hydrochloride and memantine hydrochloride had similar dissolution profiles to
one
another.
51
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
The f2 function values for donepezil hydrochloride and memantine
hydrochloride dissolution profiles were calculated based on the dissolution
profile
data of FIG. 3. Here, the standard time was taken to be a dissolution time of
8
hours or 4 hours. The results are shown in FIG. 4.
For Example 7, the f2 function value for solution B was 50, showing that the
donepezil hydrochloride and memantine hydrochloride dissolution profiles were
equivalent. This preparation is a composition for which donepezil
hydrochloride
and memantine hydrochloride can be made to be sustained-release with the same
dissolution profile in the same composition.
For Example 8, in the case of taking the standard time to be 4 hours, the f2
function value for solution A was 38, and the f2 function value for solution B
was 47,
and hence the dissolution profiles were found to be similar, showing that this
preparation is useful for releasing the drugs within 4 hours after
administration.
(Equivalency of dissolution profiles between dissolution test solutions)
The proportion of the dissolution ratio in solution A to the dissolution ratio
in
solution B for each of donepezil hydrochloride and memantine hydrochloride is
shown in FIG. 3.
For Example 5, Example 6 and Example 8, the proportion of the dissolution
ratios for donepezil hydrochloride and the proportion of the dissolution
ratios for
memantine hydrochloride were each in a range of 1 0.3 at dissolution times
of 2
hours onwards. In particular, for Examples 5 and 6, the proportion of the
dissolution ratios for memantine hydrochloride was in a range of 1 0.1 at
dissolution times of 1 hour onwards.
The f2 function values for the dissolution profiles in solution A and solution
B
were calculated for each of donepezil hydrochloride and memantine
hydrochloride
52
Our Ref: E0006 UP31W/KAN CA 02604617 2007-10-12
based on the dissolution profile data of FIG. 3. Here, the standard time was
taken
to be a dissolution time of 8 hours or 4 hours. The results are shown in FIG.
5.
For Example 5 and Example 6, the f2 function value was greater than 50 for
each of the drugs, and hence it was found that the dissolution profiles were
not
affected much by the pH of the dissolution test solution. These compositions
are
useful as preparations not much affected by the gastric emptying time.
Industrial Applicability
According to the composition of the present invention, not only can the
effects of each of at least two kinds of anti-dementia drugs be achieved, but
moreover there can be provided a novel therapeutic method due to a synergistic
effect between these anti-dementia drugs. In particular, according to the
present
invention, there can be provided a composition containing anti-dementia drugs
in
which dissolution is controlled in accordance with the symptoms and state of
the
patient and the therapeutic method. Furthermore, according to the composition
of
the present invention, there can be provided a medicine that gives excellent
compliance and is of excellent quality, and can be taken without anxiety by a
patient exhibiting symptoms of dementia, or in which the burden on a care-
giver
administering the medicine is reduced. Furthermore, according to the present
invention, design of a preparation conforming to intended objectives with
regard to
controlling release of the anti-dementia drugs can be carried out easily
without
using a special manufacturing apparatus, and moreover there can be provided a
simple, convenient manufacturing method for a pharmaceutical composition in
which the anti-dementia drugs are stabilized.
53
